<DOC>
	<DOCNO>NCT00775632</DOCNO>
	<brief_summary>Graft versus host disease ( GVHD ) one common complication stem cell transplant . This complication , happen new stem cell donor attack cell body transplant recipient . Recently , antibody ( protein ) call alemtuzumab Campath find effective prevention Graft v . Host Disease . Previous study show low risk GVHD alemtuzumab , however risk disease recurrence high . Previous study use high dose alemtuzumab . The purpose study : - To find lower dose alemtuzumab , serious GVHD prevent without increase risk relapse ( condition get bad ) . - To find whether low dose alemtuzumab combination cyclosporine prevent GVHD effectively compare current standard care increase risk recurrence .</brief_summary>
	<brief_title>Alemtuzumab Cyclosporine Prevention Graft v Host Disease After Stem Cell Transplants</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>Diagnosis hematological malignancy Peripheral blood source stem cell Able give inform consent Availability 6/6 match sibling donor Fit transplant use conventional reduced intensity approach AST/ALT &gt; 3 x IULN time transplant Serum creatinine &gt; 1.5 x IULN time transplant Prior allogeneic transplant Syngeneic donor Active uncontrolled infection HIV positive Pregnancy time BMT</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Graft Versus Host Disease</keyword>
	<keyword>Alemtuzumab</keyword>
	<keyword>Campath</keyword>
	<keyword>Bone Marrow Transplants</keyword>
</DOC>